Gabasync (original) (raw)
Gabasync is an ineffective treatment promoted for methamphetamine addiction, although it had also been claimed to be effective for dependence on alcohol or cocaine. It was marketed as PROMETA. The treatment, based loosely on the research of Spanish psychologist Juan Jose Legarda, involved a combination of three medications (gabapentin, flumazenil and hydroxyzine) as well as therapy. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not. Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond trader. Hythiam has sought to patent the protocol and charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam). Lower rates are offered to the cri
| Property | Value |
|---|---|
| dbo:abstract | Gabasync is an ineffective treatment promoted for methamphetamine addiction, although it had also been claimed to be effective for dependence on alcohol or cocaine. It was marketed as PROMETA. The treatment, based loosely on the research of Spanish psychologist Juan Jose Legarda, involved a combination of three medications (gabapentin, flumazenil and hydroxyzine) as well as therapy. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not. Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond trader. Hythiam has sought to patent the protocol and charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam). Lower rates are offered to the criminal justice system, where it has been used in several drug court pilot programs. In November 2011, the results of a double-blind, placebo-controlled study (financed by Hythiam and carried out at UCLA) were published in the peer-reviewed journal Addiction. It concluded that Gabasync is ineffective: "The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving." (en) |
| dbo:wikiPageExternalLink | http://www.clinicaltrials.gov/ct/show/NCT00260481%3Forder=1 http://www.clinicaltrials.gov/ct/show/NCT00262639%3Forder=2 https://web.archive.org/web/20061217110247/http:/www.prometainfo.com/pi/ https://web.archive.org/web/20090612134220/http:/media.thenewstribune.com/smedia/2007/10/24/08/prometa_report.source.prod_affiliate.5.pdf |
| dbo:wikiPageID | 8529764 (xsd:integer) |
| dbo:wikiPageLength | 16309 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1092139943 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Hydroxyzine dbr:Peer-reviewed dbr:University_of_Washington dbr:Collin_County,_Texas dbr:Conflict_of_interest dbr:Covington,_Louisiana dbr:Chris_Farley dbr:Cocaine dbr:Fulton_County,_Georgia dbr:Gabapentin dbr:Gary,_Indiana dbr:Open-label_trial dbc:Drug_rehabilitation dbr:Lindsay_Lohan dbr:MTV dbr:Star_(magazine) dbr:Marketing_of_off-label_use dbr:Physical_dependence dbr:Addiction dbr:True_Life dbr:UCLA dbr:Drug_court dbr:60_Minutes dbr:Alcohol_(drug) dbc:Alcohol_abuse dbr:Federal_Way,_Washington dbr:Flumazenil dbr:Food_and_Drug_Administration dbr:Terren_Peizer dbr:National_Association_of_Drug_Court_Professionals dbc:Substance_dependence dbr:John_Ladenburg dbr:Karen_Freeman-Wilson dbr:Pierce_County,_Washington dbr:Methamphetamine dbr:Pilot_program |
| dbp:wikiPageUsesTemplate | dbt:Short_description |
| dcterms:subject | dbc:Drug_rehabilitation dbc:Alcohol_abuse dbc:Substance_dependence |
| rdfs:comment | Gabasync is an ineffective treatment promoted for methamphetamine addiction, although it had also been claimed to be effective for dependence on alcohol or cocaine. It was marketed as PROMETA. The treatment, based loosely on the research of Spanish psychologist Juan Jose Legarda, involved a combination of three medications (gabapentin, flumazenil and hydroxyzine) as well as therapy. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not. Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond trader. Hythiam has sought to patent the protocol and charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam). Lower rates are offered to the cri (en) |
| rdfs:label | Gabasync (en) |
| owl:sameAs | wikidata:Gabasync https://global.dbpedia.org/id/Fosy7 |
| prov:wasDerivedFrom | wikipedia-en:Gabasync?oldid=1092139943&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Gabasync |
| is dbo:wikiPageRedirects of | dbr:Prometa dbr:Hythiam dbr:Juan_Jose_Legarda |
| is dbo:wikiPageWikiLink of | dbr:Prometa dbr:Hythiam dbr:Juan_Jose_Legarda |
| is foaf:primaryTopic of | wikipedia-en:Gabasync |